[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"uterine-fibroid\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:uterine-fibroid":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,39,70,99,123,145],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100527892","bearing-nspva-embolization-for-uterine-artery-embolization-better-uae-100527892",false,"NCT06153667","Bearing nsPVA Embolization for Uterine Artery Embolization (BETTER-UAE)","Prospective, Multi-Center Study Using Bearing nsPVA Embolization Particles for the Treatment of uTErine fibRoids With Uterine Artery Embolization","BETTER-UAE","Inclusion Criteria:\n\n* Adult women ≥ 18 years old at the time of enrollment.\n* Subject has symptomatic uterine fibroid(s), suitable to embolization.\n* Subject provides written informed consent.\n\nExclusion Criteria:\n\n* Subject is pregnant.\n* Subject has suspected pelvic inflammatory disease or any other pelvic infection.\n* Subject has any malignancy of the pelvic region, (e.g., endometrial neoplasia).","FEMALE","18 Years",{"count":20,"type":21},100,"ESTIMATED","OBSERVATIONAL","This is a prospective, multicenter, observational, post-market clinical follow-up study in subjects treated with Bearing nsPVA Embolization Particles for uterine fibroid embolization. Data collection will include safety and performance outcome relating to the use of Bearing nsPVA, through 6 months.",[25],"Uterine Fibroid","RECRUITING","2026-05-28",{"date":29,"type":30},"2026-05-29","ACTUAL",{"date":32,"type":30},"2024-08-22",{"date":34,"type":21},"2026-12",{"name":36,"class":37},"Merit Medical Systems, Inc.","INDUSTRY",4,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":46,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100606251","the-impact-of-a-novel-gnrh-antagonist-with-add-back-therapy-for-treatment-of-uterine-fibroids-and-endometriosis-on-hemostasis-parameters-100606251","NCT07173127","The Impact of a Novel GnRH Antagonist With Add-back Therapy for Treatment of Uterine Fibroids and Endometriosis on Hemostasis Parameters","The Effect of a Novel Combined Hormonal Treatment Containing a GnRH-antagonist for Uterine Fibroids and Endometriosis on Hemostasis Parameters: a Prospective Cohort Study","Inclusion Criteria:\n\n* Women consulting at the DFEA of the HUG, who are prescribed Ryeqo® for a qualified medical condition\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* Unable to speak and\u002For read French\n* Having used either an oestro-progestin pill (oral, patch or vaginal ring) or oral estrogens in the past 3 months, or DMPA or nomegestrol acetate\n* Women not having given their consent to participate in the study",true,{"count":48,"type":21},30,"INTERVENTIONAL",[51],"NA","Uterine fibroids and endometriosis are two frequent diseases among women of reproductive age. They can be responsible for chronic and\u002For menstrual pelvic pain and abnormal uterine bleeding. The first-line management of these conditions relies on medical treatment. Hormonal treatment with contraceptive pill can be effective, although up to 30% of patients do not respond to this line of treatment. In this context, GnRH antagonists have been introduced. By suppressing ovulation, they inhibit the action of the gonadal axis and thus can reduce bleeding and pain associated with uterine fibroids and endometriosis. More recently, the GnRH antagonist known as Relugolix has been associated with a low-dose oestradiol and progesteron-line molecule, a medication known as Ryeqo. The goal of this type of treatment is to suppress ovulation while also minimizing symptôms which may derive from lack of oestrogen and progesterone in reproductive age women.\n\nWhile Ryeqo's efficacy has been proven by multiple large randomized controlled trials, its impact on blood coagulation has yet to be determined. Venous thromboembolism (VTE) is the main, potentially fatal, dleterious effect of oestrogen-containing hormonal treatmen, such as combined oral contraceptives (COC). Several epidemiological studies have found a 3-6 increase in the risk of VTE among women on COC. The thrombogenic risk can be assessed by measuring specific blood biomarkers, which are known to be correlated to the thrombogenic phenotype and allow an overview of the VTE risk prior to conducting large population-scale studies directly measuring the adverse event's prevalence.\n\nThe aim of this study is to document the effects of Ryeqo® on hemostasis parameters in order to estimate the risk of VTE associated with its employ. An improved understanding of the VTE risk associated with Ryeqo® will allow to adapt hormonal treatment based on each woman's personal risk profile.\n\nThe study will be explained to all women whose medical condition allows the prescription of Ryeqo. All women who give their consent to participate in the study will have a urinary pregnancy test and a blood sample drawn before beginning treatment with Ryeqo. A second visit will be scheduled at 3 months, throughout which a second blood sample will be drawn. A questionnaire including socio-demographic data and clinical symptoms will be completed both on the first and the second visit.",[25],[55,56,57,58],"Uterine fibroids","Endometriosis","GnRh Antagonist","Hemostasis markers","2026-04-28",{"date":61,"type":30},"2026-04-29",{"date":63,"type":30},"2025-09-30",{"date":65,"type":21},"2027-03-30",{"name":67,"class":68},"University Hospital, Geneva","OTHER",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":76,"targetDuration":78,"studyType":22,"phases":4,"briefSummary":79,"conditions":80,"keywords":86,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100613664","a-prospective-validation-study-of-radiomics-in-the-differential-diagnosis-of-uterine-leiomyoma-and-uterine-sarcoma-100613664","NCT07269535","A Prospective Validation Study of Radiomics in the Differential Diagnosis of Uterine Leiomyoma and Uterine Sarcoma","1. Inclusion Criteria:\n\n   1.1 Patients clinically evaluated and radiologically examined (including MRI, particularly T2WI and DWI sequences) who are diagnosed with uterine leiomyoma or considered highly suspected of uterine sarcoma, in combination with preliminary pathological findings.\n\n   1.2 Patients scheduled for surgical treatment or those eligible for long-term standardized follow-up.\n\n   1.3 Patients who are able to understand the study procedures and voluntarily sign the written informed consent form.\n2. Exclusion Criteria:\n\n2.1 Patients with severe organic diseases or a previous confirmed diagnosis of other malignant uterine tumors.\n\n2.2 Patients unable to complete baseline examinations, unable to comply with long-term follow-up, or unwilling to provide written informed consent.",{"count":77,"type":21},500,"5 Years","In our previous study, based on the multi-center clinical big data collected from January 2012 to January 2025, we have completed the construction of a multimodal early warning model for the malignant transformation of uterine fibroids. The model was mainly based on T2WI and DWI sequences, and was trained and optimized by support vector machine (SVM) algorithm. In the retrospective study and internal validation, the model shows high sensitivity and specificity, which preliminarily proves that it has good application potential in identifying high-risk groups and predicting the risk of malignant transformation of uterine fibroids.\n\nHowever, there are still some limitations in retrospective studies and internal validation results, and its application value, universality and stability in real clinical environment have not been fully verified. Therefore, we plan to conduct a prospective validation study in consecutive patients enrolled after January 2025 to evaluate the clinical performance and generalization of the model in predicting the malignant tendency or risk of malignant transformation of uterine fibroids through practical application in the real population, and further analyze the operability in the actual diagnosis and treatment process and the potential value for patient management. This study will provide reliable evidence for early screening, follow-up management and individualized treatment of high-risk population, and has important clinical and public health significance for improving the early diagnosis rate, reducing the risk of malignant transformation and improving the prognosis of patients with uterine fibroids.",[25,81,82,83,84,85],"Uterine Sarcoma","AI (Artificial Intelligence)","Radiomic","Prospective Observational Study","MRI",[87,25,88,82,83,85],"prospective observational study","uterine sarcoma","NOT_YET_RECRUITING","2025-11-26",{"date":92,"type":30},"2025-12-08",{"date":94,"type":21},"2025-11-30",{"date":96,"type":21},"2050-01-01",{"name":98,"class":68},"Tongji Hospital",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":105,"enrollmentInfo":106,"targetDuration":108,"studyType":22,"phases":4,"briefSummary":109,"conditions":110,"keywords":111,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":5},"100468963","post-exablate-pregnancy-outcomes-registry-study-exablate-treatment-of-symptomatic-uterine-fibroids-100468963","NCT05386615","Post-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids","Inclusion Criteria: - - Eligibility is as per the symptomatic fibroids device indication. - All registry-consented patients following the treatment of their fibroid(s) with the Exablate system. Exclusion Criteria: -","50 Years",{"count":107,"type":21},200,"2 Years","The goal of this Registry Study is to capture clinical pregnancy outcomes and fibroid treatment background data for any subject post-Exablate treatment for their symptomatic fibroids.",[25],[112,113],"Uterine Fibroids","Exablate","2025-04-29",{"date":116,"type":30},"2025-04-30",{"date":118,"type":30},"2016-02-16",{"date":120,"type":21},"2026-12-31",{"name":122,"class":37},"InSightec",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":49,"phases":132,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":69},"100570271","phase-2-evaluation-of-uterine-fibroids-by-ceus-and-shape-pre-and-post-uae-100570271","NCT06705075","Evaluation of Uterine Fibroids by CEUS and SHAPE Pre and Post UAE","Evaluation of Uterine Fibroids by Contrast Enhanced Ultrasound (CEUS) and Subharmonic- Aided Pressure Estimation (SHAPE) Pre and Post-Uterine Artery Embolization (UAE)","Inclusion Criteria:\n\n* Be a female diagnosed with endometrial cancer and scheduled for UAE.\n* Be over the age of 18 years.\n* If the subject is of child-bearing potential, must have a negative pregnancy test.\n* Be conscious and able to comply with study procedures.\n* Have read and signed the IRB approved consent form for participating in the study.\n\nExclusion Criteria:\n\n* Females who are pregnant or nursing.\n* Patients who have received an investigational drug in the 30 days before study drug administration, or will receive one within 72 hours afterwards.\n* Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable. For example:\n* Patients on life support or in a critical care unit.\n* Patients with clinically unstable cardiac arrhythmias, such as recurrent ventricular tachycardia.\n* Patients with recent cerebral hemorrhage.\n* Patients who have undergone surgery within 24 hours prior to the study sonographic examination.\n* Patients with congenital heart defects.\n* Patient with a known allergy to Definity.",{"count":131,"type":21},80,[133],"PHASE2","This study goals are to determine the patterns of uterine fibroid vascularity pre and post UAE using CEUS resulting in an alternative to gadolinium-enhanced MRI that is less expensive, has less contra-indications and side effects, is real time, and noninvasive helping physicians to evaluate the result of UAE procedures. Also, this study will evaluate uterine fibroid pressures using SHAPE, comparing the results with normal myometrium tissue in order to determine its characteristics and tissue differences, which we believe will lead to the development of a new biomarker for the diagnosis and treatment of uterine fibroids.",[25],"2025-04-07",{"date":138,"type":30},"2025-04-10",{"date":140,"type":30},"2025-01-27",{"date":142,"type":21},"2026-09-30",{"name":144,"class":68},"Thomas Jefferson University",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":46,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":161,"locationsCount":4},"100503806","epidemiology-and-risk-factors-of-uterine-fibroids-in-china-100503806","NCT05840042","Epidemiology and Risk Factors of Uterine Fibroids in China","Inclusion Criteria:\n\n* Current place of residence≥ 6 months;\n* No serious mental illness or mental abnormality;\n* Those who agree to participate in this survey and cooperate in completing the questionnaire.\n\nExclusion Criteria:\n\n\\-",{"count":152,"type":21},20000,"Uterine fibroids are the most common form of benign uterine tumors in the uterine muscle layer, which had a certain rate of malignancy, but it is rare. The prevalence of uterine fibroids estimates range from 4.5% to 68.6% depending on study population and diagnostic methodology. The prevalence of fibroids has been historically underestimated by epidemiologic studies which focused mainly on symptomatic women, leaving behind a large population of asymptomatic women and women who underreport their symptoms. What investigators don't know was which women who have fibroids will develop clinical symptoms and which women who have an operation of myomectomy will relapse. The purpose of this study is to investigate the prevalence, incidence and risk factors for the development of uterine fibroids in Chinese women.",[25],"2023-06-20",{"date":157,"type":30},"2023-06-22",{"date":159,"type":21},"2023-06-19",{"date":120,"type":21},{"name":162,"class":68},"Shixuan Wang"]